SOMAVAC Raises $1.2M Series A Funding to Revolutionize Surgical Care with Innovative Negative Pressure Therapy

SOMAVAC® Medical Solutions, Inc., a pioneering MedTech company at the forefront of developing innovative technology platforms, is excited to announce the successful raise of $1,200,000 in new funding. This exciting investment marks a significant milestone for SOMAVAC as it continues its mission to mitigate surgical complications, enhance treatment protocols, and ultimately reduce the overall cost of healthcare. The funds will be strategically deployed to further advance the company’s flagship product, SOMAVAC® Deep Tissue Negative Pressure Therapy—the first powered negative pressure therapy device cleared for seroma prophylaxis. This breakthrough technology is designed to benefit patients undergoing breast reconstruction and mastectomies by efficiently removing fluid as it is produced, obliterating dead space, and securing tissues together, thereby preventing the formation of seromas that can lead to complications such as surgical site infections and wound dehiscence. In addition to its revolutionary seroma prophylaxis application, the recent funding will accelerate the development of an innovative patent that integrates closed-incision negative pressure wound therapy (ciNPWT) with the existing deep tissue methodology. This comprehensive device offers surgeons an unprecedented ability to optimize surgical outcomes by applying negative pressure both inside the surgical site and along the exterior of the incision, creating a novel category within the medical device landscape. With the potential to impact a $1.1 billion immediate US market, this advancement not only promises enhanced patient safety but also broadens the clinical utility of negative pressure therapy. The infusion of capital is poised to drive the expansion of SOMAVAC’s research, development, and commercialization efforts as the company continues to break new ground in medical technology innovation.